C3 Glomerulopathy: Pathogenesis and Treatment
Overview
Authors
Affiliations
C3 glomerulopathy (C3G) is a rare set of kidney diseases with 2 patterns: C3 glomerulonephritis (C3GN) and dense deposit disease. Pathogenesis of both diseases is due to complement dysregulation in the alternative pathway. Acquired or genetic alterations of the regulatory proteins of the complement pathway result in C3G. Although the disease is characterized by low C3 levels in serum and C3-dominant staining by immunofluorescence on biopsy, other disease entities such as infection-related glomerulonephritis and masked monoclonal deposits can present similarly. Both the C3GN and dense deposit disease variants of C3G are progressive and recur in transplanted kidneys. Although no direct treatment is available, complement blockers are either available or in the clinical trial phase. This review will survey the pathogenesis of C3GN and current treatment options.
Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy.
Nester C, Eisenberger U, Karras A, le Quintrec M, Lightstone L, Praga M Kidney Int Rep. 2025; 10(2):432-446.
PMID: 39990880 PMC: 11843281. DOI: 10.1016/j.ekir.2024.10.023.
Zhang J, Yu H, Chen Y, Chen Q, Zheng X, Luo J BMC Pediatr. 2025; 25(1):47.
PMID: 39833736 PMC: 11744802. DOI: 10.1186/s12887-025-05415-z.
Bartoli G, Dello Strologo A, Arena M, Galeandro E, Ferro M, Diomedi-Camassei F Am J Case Rep. 2024; 25:e944208.
PMID: 39628044 PMC: 11627295. DOI: 10.12659/AJCR.944208.
Membranoproliferative Glomerulonephritis over 20 Years at a Tertiary Referral Center in the UK.
OKeeffe H, Storrar J, Ramakrishna C, Metaoy S, Chrysochou C, Chinnadurai R Glomerular Dis. 2024; 4(1):159-166.
PMID: 39473993 PMC: 11521467. DOI: 10.1159/000540672.
Kanzaki M, Kurahashi M, Watanabe K, Nishikawa M, Fukuoka K, Shimada N CEN Case Rep. 2024; .
PMID: 39264532 DOI: 10.1007/s13730-024-00928-5.